Multiple myeloma (MM) is characterized by recurrent chromosomal translocations. In t(4;14) MM, the MM SET domain (MMSET) protein is universally overexpressed and has been suggested to have an important tumorigenic role. However, the exact molecular targets underlying MMSET activity are not well understood. Here, we found in t(4;14) MM cells that MMSET knockdown decreases interferon regulatory factor 4 (IRF4) expression, and ectopic MMSET increases IRF4 expression, suggesting that MMSET is an upstream regulator of IRF4. Further analyses indicated an interaction between MMSET and nuclear factor-κB, which both bind to the IRF4 promoter region. A luciferase reporter assay showed that MMSET is an important functional element for the IRF4 promoter. MMSET knockdown induces apoptosis and potentiates the effects of bortezomib in vitro and in vivo. Importantly, we found that bortezomib could reduce expression of MMSET and IRF4. This might partly explain the additive effect of combining MMSET knockdown and bortezomib treatment. These results identify MMSET as a key regulator involved in the regulatory network of transcription factor IRF4, which is critical for MM cell survival, suggesting that the combination of MMSET inhibition and bortezomib is likely to improve patient outcome in MM.
INTRODUCTION
Multiple myeloma (MM) is a genetically complex disease that is becoming more common in today's ageing population. In the past decade, it has become apparent that~50% of MMs harbor recurrent translocations involving the immunoglobulin heavy chain locus on chromosome 14q32. [1] [2] [3] The translocation t(4;14) (p16;q32) is one of the most common translocation in MMs, affecting 15% of patients, and is associated with very poor prognosis. 4 The t(4;14) translocation leads to the simultaneous overexpression of two genes, FGFR3 (fibroblast growth factor receptor 3) and MMSET (multiple myeloma SET domain). FGFR3 has transforming activity in vitro and in vivo, but~30% of t(4;14) MM patients do not express FGFR3, whereas overexpression of MMSET isoforms is a universal feature of t(4;14) cases. [5] [6] [7] Furthermore, the poor prognosis of t(4;14) persists irrespective of FGFR3 expression. 7 These data suggest that MMSET may be the critical oncogene in this translocation.
The MMSET protein contains AWS (associated with set)-SET-PostSET domains that are highly conserved with yeast H3K36specific methyltransferase Set2. 8 It was first reported that the MMSET protein is an H4K20 methyltransferase with characteristics of a transcriptional corepressor. 9 Later, several reports suggested that MMSET could generate numerous different histone marks, including H3K4me2, H3K9me2, H3K27me3, H3K36me2, H3K36me3 and H4K20me2. [10] [11] [12] [13] [14] It has been recently suggested that the principal physiologic activity of MMSET at the chromatin is dimethylation of H3K36. 15 Downregulation of MMSET expression in MM cell lines indicated that t(4;14) MM cells rely on MMSET expression for clonogenic growth and tumorigenicity in vivo. 1 These results provide the first direct evidence that MMSET is an oncogene and has a significant role in t(4;14) MM. Later, several groups reported that depletion of MMSET could also inhibit proliferation and induce cell cycle arrest and apoptosis. 9, [15] [16] [17] Consistent with MMSET knockdown results, wild-type MMSET (but not MMSET catalytic mutants) could restore proliferation and colony formation of t(4;14) MM cells upon MMSET deletion. Furthermore, complementation of MMSET knockout cells with wild-type MMSET (rather than catalytic mutants) could restore their tumorigenicity in vivo. 15, 18 These data further confirmed that MMSET is an oncogene and that its oncogenic role is dependent on its catalytic activity. Despite the aforementioned data, the exact molecular targets underlying MMSET activity are not well understood.
Here, we identified downstream functional targets of MMSET using gene expression array analysis. We found that MMSET could regulate the expression of interferon regulatory factor 4 (IRF4), which is critical for the survival of MM. Further analysis indicated that MMSET binds to the promoter region of IRF4 and could regulate IRF4 expression by acting as a coactivator of nuclear factor-κB (NF-κB). We also found that MMSET knockdown could potentiate the antimyeloma effects of bortezomib in vitro and in vivo, suggesting that the combination of MMSET inhibition and bortezomib could have a therapeutic potential.
MATERIALS AND METHODS

Cell lines and cell culture
Human t(4;14) MM cell lines KMS11, KMS12BM, KMS18, KMS28BM and U266, were maintained in RPMI-1640, supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin. All MM cell lines, except KMS12BM and U266, are t(4;14) positive. All MM cell lines are from the laboratories of Professor Rafael Fonseca and Professor Leif Bergsagel (Mayo Clinic, Scottsdale, AZ, USA) and have been tested, authenticated and previously used in the peer-reviewed articles produced by those laboratories. [19] [20] [21] HEK293T cells (from ATCC, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium, supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin. All cells were grown at 37°C in a humidified atmosphere with 5% CO 2 .
Virus production and infection
The sequences encoding short hairpin RNAs (shRNAs) against MMSET or IRF4 ( Supplementary Table 1 ) were cloned into lentiviral vector pLKO.1. The sequence encoding MMSET was amplified from KMS11 and cloned into the pLN1 vector. 22 All clones were verified by sequencing. Lentivirus particles were prepared as described previously. 22 Cells were infected with lentiviruses in the presence of 8 μg/ml polybrene (Sigma-Aldrich, St Louis, MO, USA). Protein expression was analyzed 3 days after infection. The KMS11 cell line with ectopic expression of MMSET was generated using puromycin (3 μg/ml; Sigma-Aldrich) selection.
Microarray analysis and quantitative PCR
Cells were treated with shRNAs for 48 h. Total RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany). Gene expression was performed using the GeneChip Human Genome U133 plus 2.0 array (Affymetrix, Santa Clara, CA, USA) following the manufacturer's instructions. Data analysis was performed using the GeneSpring software from Agilent Technologies (Santa Clara, CA, USA). The data were deposited in Gene Expression Omnibus with accession no. GSE59424. The cDNA was created using iScript RT Supermix (Bio-Rad Laboratories, Hercules, CA, USA). The 7300 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA) was used for quantitative PCR (qPCR) amplification according to the iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories) protocol. Relative quantification of gene expression was carried out using β-actin as an internal standard and the comparative threshold cycle method. The primers for qPCR are listed in Supplementary Table 2 .
Immunoblot and co-IP analysis
Cells were collected and lysed in RIPA buffer as described previously. 23 Equal amounts of protein were separated on sodium dodecyl sulfatepolyacrylamide gels and transferred to PVDF membranes. The blots were probed with antibodies against c-Myc (sc-40), His-probe (sc-53073), IRF4 (sc-56713), NF-κB p65 (sc-8008), PARP (sc-8007) and β-actin (sc-69879) (Santa Cruz Biotechnology, Dallas, TX, USA), phospho-NF-κB p65 (Ser536) (No. 3033), IκBα (No. 9242), H3K36Me3 (No. 4909) and histone 3 (No. 9715) (Cell Signaling Technology, Boston, MA, USA), MMSET (No. 75359) (Abcam, Cambridge, UK) and H3K36Me2 (No. 39255) (Active Motif, Carlsbad, CA, USA). Luminol Reagent (sc-2048) (Santa Cruz Biotechnology) was used for detection on film. Antibodies against NF-κB p65 (sc-372), NF-κB p50 (No. 3035), MMSET (rabbit polyclonal) 21 and normal rabbit IgG (No. 2729) were used for co-immunoprecipitation (Co-IP). The association between MMSET and NF-κB was detected by immunoblots with antibodies against MMSET (No. 75359) and NF-κB p65 (sc-8008). Densitometry analyses for the immunoblots were performed using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). The levels of each of the proteins were normalized with respective loading controls β-actin or histone 3.
Cell proliferation assay and apoptosis analysis
Cells were infected with shRNAs and cultured for 48 h. Then, cells were pulsed with bortezomib (Velcade) for 8 h to mimic their rapid turnover in humans. Cells were cultured for a further 48 h and subsequently analyzed using the MTS colorimetric assay (Promega, Fitchburg, WI, USA) as described previously. 24 For apoptosis analysis, cells were infected with shRNAs and cultured for 96 h, then analyzed for the level of apoptosis by flow cytometry using propidium iodide staining as described previously. 25 
ChIP assay
Chromatin immunoprecipitations (ChIPs) were performed using Magna Chip G (no. 17-611; Merck Millipore, Billerica, MA, USA) according to the manufacturer's protocol. Antibodies for ChIP were NF-κB p65 (sc-372 X), H3K36Me3 (no. 4909), histone H3 (no. 4620) and normal rabbit IgG (no. 2729) (Cell Signaling Technology), MMSET (no. 75359) (Abcam) and normal mouse IgG (sc-3877) (Santa Cruz Biotechnology). Input controls consisted of 2% chromatin before immunoprecipitation. Purified DNA from crosslinked cells was used for qPCR with a subset of primers across IRF4 promoter ( Supplementary Table 3 ). Data obtained by qPCR were plotted as fold enrichment.
Luciferase reporter assay
The IRF4 promoter region was PCR amplificated from KMS11 genomic DNA using forward and reverse primers containing XhoI and NcoI restriction sites ( Supplementary Table 4 ). After restriction digestion, the fragments were cloned into the pGL3-Control vector (digested with XhoI and HindIII to delete the SV40 promoter) to generate the IRF4 promoter constructs, pGL3-IRF4_ProL(−3406/+91) and pGL3-IRF4_ProS (−1502/+91).The constructs were verified by nucleotide sequencing. KMS11 cells were treated with shRNAs and cultured for 48 h. Cells were cotransfected with firefly luciferase reporter constructs and Renilla luciferase reporter vector pRL-SV40 (Promega) in a ratio of 400:1 using X-tremeGENE transfection reagent (Roche Diagnostics, Basel, Switzerland). Cells were harvested after 24 h and analyzed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega). The promoter activity was calculated by dividing the luciferase activity of constructs by the internal Renilla luciferase activity.
Myeloma xenograft model and therapy
The animal experiment was approved by an Institutional Animal Care and Use Committee. Six-week-old male nonobese diabetic/severe-combined immunodeficiency (NOD/scid) mice were purchased from InVivos Pte Ltd (Singapore) and maintained under specific pathogen-free conditions at National University of Singapore (Singapore, Singapore). Animal size was determined by the Resource Equation (E = 20). Cultured cells were suspended at 5 × 10 7 ml − 1 in buffer containing an equal volume of phosphate-buffered saline (PBS) and Marigel (no. 354234; BD Biosciences, Franklin Lakes, NJ, USA). The mice were injected subcutaneously in the left flank with 1 × 10 7 KMS11/ShLuc cells and in the right flank with 1 × 10 7 KMS11/ShMMSET cells, and randomly assigned into two treatment groups (6 mice per group). Treatments were started on day 2 after cell inoculation (no blinding). The first and second groups served as the control (PBS) and bortezomib (0.125 mg/kg) groups, respectively. Drugs were administered by intraperitoneal injection on a twice-weekly schedule for 2 weeks. All mice were killed 30 days after the initial injection, and tumors were collected and weighed. The tumor weight data from each group was normally distributed. The variances were also relative similar among groups (0.271, 0.014, 0.137 and 0.011 in the ShLuc-PBS, ShLuc-bortezomib, ShMMSET-PBS and ShMMSET-bortezomib groups respectively).
Statistical analysis
Results were expressed as mean values ± s.d. derived from three separate experiments and the Student's t-test was used for evaluating statistical significance after checking for normal distribution. Two-sided tests were used with significance defined as Po0.05.
RESULTS
MMSET regulates expression of IRF4
To determine the downstream functional targets of MMSET, the t(4;14) MM cell line KMS11 was infected with MMSET shRNAs and the differentially expressed genes were analyzed by gene expression microarrays. The microarray analysis indicated that 321 genes were downregulated and 375 genes were upregulated upon MMSET knockdown (based on a threshold of twofold or greater difference in signal intensity; Supplementary Figure 1 ). Functional clustering analysis using DAVID (the Database for Annotation, Visualization and Integrated Discovery) Bioinformatics Resource 6.7 indicated that MMSET knockdown affected key pathways essential for cell cycle/division, response to nutrient, nucleotide binding and lymphocyte activation (Supplementary Table 5 ). Previous studies suggested the importance of NF-κB signaling in MM. 26 Our gene array data analysis indicated that MMSET knockdown affected 17 NF-κB target genes in t(4;14) MM cells (Figure 1a) . Importantly, the knockdown reduced the expression of IRF4, which is required for myeloma cell survival. 27 qPCR and immunoblot analyses confirmed that MMSET shRNAs could decrease IRF4 expression in t(4;14) MM cells (Figures 1b and c) . MMSET shRNAs had minimal effects on IRF4 expression in non-t(4;14) MM cells ( Supplementary Figure 2) . The MMSET protein contains the SET domain, which is highly conserved with the yeast H3K36-specific methyltransferase Set2. 8 As expected, the levels of H3K36me2 and H3K36Me3 were reduced upon MMSET knockdown (Figure 1c ). Previously, c-myc was identified as a direct target of IRF4 in activated B cells and myeloma. 27 As expected, c-myc protein levels were also reduced upon MMSET knockdown (Figure 1c ). Simultaneously, apoptosis was induced as demonstrated by the reduced levels of PARP, PARP cleavage and significant increase in the sub-G1 fraction upon MMSET knockdown (Figures 1c and d) . We next transfected the MMSET vector into KMS11 cells. qPCR and immunoblot analyses indicated that ectopic MMSET could increase IRF4 expression (Figures 1e and f) . Further analysis indicated that the protein levels of c-myc, H3K36me2 and H3K36Me3 were also increased upon MMSET overexpression. To determine the importance of IRF4 for MM survival, we knocked down IRF4 expression with shRNAs. IRF4 knockdown was confirmed by qPCR and immunoblot analysis. As expected, IRF4 knockdown also reduced c-myc protein levels and induced apoptosis in t(4;14) MM ( Figure 2) . These data suggest that IRF4 is an important functional target underlying MMSET.
MMSET associates with NF-κB and binds to IRF4 promoter Previously published data has suggested that IRF4 is one of NF-κB's downstream targets. 27 To explore the mechanism by which MMSET regulates IRF4 expression, we examined whether the regulation of IRF4 expression by MMSET is associated with NF-κB in t(4;14) MM. First, we performed a co-IP assay to determine the interaction between MMSET and NF-κB. As shown in Figure 3a , MMSET antibody could pull down NF-κB p65 protein, whereas the NF-κB p65 antibody could pull down MMSET protein. As shown in Supplementary Figure 3 , NF-κB p50 antibody could also pull down MMSET. These results demonstrated that MMSET forms complexes with the NF-κB proteins. Furthermore, our ChIP assay results indicate that MMSET is enriched at the promoter and coding regions of IRF4 (Figures 3b and c) , and that H3K36Me3 is enriched at the IRF4 coding region but that its level is reduced upon MMSET knockdown (Figure 3d ). Consistent with earlier studies that have shown that the levels of H3K36Me3 peak near the 3′ end of genes, 28, 29 we found that this trend is also true for IRF4. Further analysis found that NF-κBp65 is also bound to the promoter region of IRF4 and that its binding is independent of MMSET ( Figure 3e ). We also performed luciferase reporter assay in KMS11 cells and found that the activity of IRF4 promoters were significantly decreased upon MMSET knockdown. Furthermore, the − 3406 to +92 promoter fragment contained significantly more promoter activity compared with the − 1502 to +92 fragment in KMS11 cells (Figure 3g ). These results suggest that MMSET is an important functional element for IRF4 promoter activity. 
MMSET knockdown potentiates the effect of bortezomib in vitro and in vivo
It has been recently reported that loss of IRF4 could sensitize MM cells to bortezomib-induced apoptosis. 30 Therefore, we hypothesized that MMSET knockdown could have a similar effect. Cell proliferation assays showed that MMSET knockdown could potentiate the effect of bortezomib in t(4;14) MM cell lines KMS11, KMS18 and KMS28BM (Figures 4a and c) . Immunoblot analysis indicated that the combination of MMSET knockdown and bortezomib results in a greater induction of PARP cleavage compared with the single treatments (Figure 4d ). Flow cytometric analysis also indicated that the combination of MMSET knockdown and bortezomib induced apoptosis more than in the single treatments ( Supplementary Figure 4) . The combination effect was then investigated in an NOD/scid xenograft human myeloma model, in which the mouse was injected subcutaneously in the left flank with KMS11/ShLuc cells and in the right flank with KMS11/ ShMMSET cells. Bortezomib was administered by intraperitoneal injection on a twice-weekly schedule for 2 weeks. Thirty days after initial injection, tumors were collected and weighted. The results indicated that the combination of MMSET knockdown and subtherapeutic dose of bortezomib (0.125 mg/kg) significantly inhibited tumor growth, as compared with either of the single treatments (Figures 4e and f) .
Bortezomib inhibits MMSET and IRF4 expression
To explore the additive mechanism of the combination of MMSET knockdown and bortezomib, total proteins and RNAs were extract from KMS11, KMS18 and KMS28BM cells at 24 h after drug treatment. We found that in KMS11 cells, bortezomib decreased the IκBα levels and increased phosphor-p65 levels, whereas in KMS18 and KMS28BM cells, the levels of IκBα, p65 and phosphor-p65 were decreased upon bortezomib treatment. Bortezomib reduced MMSET protein levels in all of three cell lines. The aggregate effect is that IRF4 protein levels were decreased upon bortezomib treatment in all cell lines (Figure 5a ). As expected, the (e and f) The NOD/scid mice were injected subcutaneously in the left flank with 1.0 × 10 7 KMS11/ShLuc cells and in the right flank with 1.0 × 10 7 KMS11/ ShMMSET cells and randomly assigned to two treatment groups (6 mice per group). Treatments were started on day 2 after cell inoculation. Drugs were administered by intraperitoneal injection on a twice-weekly schedule for 2 weeks. All mice were killed 30 days after the initial injection, and tumors were collected and weighted. Data shown are mean ± s.d. *P o0.05 and **Po 0.01. combination of bortezomib and MMSET knockdown decreased IRF4 expression more strongly compared with that in either of the single treatments. MMSET knockdown had little effect upon NF-κB p65 and IκBα protein levels (Figure 5a ). These data combined with previous co-IP and ChIP results suggested that MMSET is an NFκB co-operator, rather than an upstream regulator. qPCR analysis indicated that bortezomib inhibited MMSET and IRF4 expression through transcription control (Figure 5b ).
DISCUSSION
MM is an incurable hematologic malignancy characterized by recurrent chromosomal translocations. 2, 31 MMSET was identified as a gene involved in the t(4;14)(p16;q32) translocation affecting 15% of patients. 4, 32 This subtype of myeloma has a poor prognosis with frequent relapse after autologous stem-cell transplantation. 4, 5, 33 MMSET is universally overexpressed in t(4;14) MM, 7 and when it is knocked down experimentally, there is inhibition of proliferation, induction of apoptosis and reduction of tumor formation, 1, 9, 15 suggesting that MMSET is central to the pathogenesis of t(4;14) MM. Furthermore, clinical evidence suggests that overexpression of MMSET might initiate myelomagenesis and supports its role in the etiology of t(4;14) MM. 34 However, the exact genetic targets underlying MMSET activity are not well understood. In this study, we show that MMSET is able to regulate IRF4 expression through transcription control.
Expression of IRF4, a member of the IRF family of transcription factors, is restricted to the immune system. IRF4 is considered to be a key regulator of several steps in lymphoid, myeloid and dendritic cell differentiation and maturation. IRF4 is induced by diverse mitogenic stimuli, including antigen receptor engagement, lipopolysaccharides and CD40 signaling. These stimuli all activate the NF-κB pathway, which leads to IRF4 promoter activation by NF-κB heterodimers. 35 IRF4 expression is observed in a wide spectrum of hematolymphoid neoplasms and in malignant melanoma. 36 Shaffer et al., 27 using a loss-of-function RNA interference-based genetic screen demonstrated that IRF4 is essential for survival of MM cells. A particularly noteworthy IRF4 target gene in MM is MYC. IRF4 binds directly to the MYC promoter region in MM cells and transactivates its expression. Conversely, MYC transactivates IRF4 by binding to an evolutionarily conserved intronic region, creating a positive autoregulatory feedback loop. 27 In our study, MMSET knockdown decreased IRF4 expression, and ectopic MMSET increased IRF4 expression, suggesting that MMSET can act as an upstream regulator of IRF4. Yang et al. 37 reported that MMSET directly interacts with NF-κB and mediates NF-κB-dependent gene activation in prostate cancer cells. Our study indicated that MMSET could also interact with NF-κB and is an important functional element for IRF4 promoter activity in t(4;14) MM. The fact that MMSET is universally overexpressed in t(4;14) MM and regulates the expression of MM survival factor IRF4 suggests that MMSET has an important role and is a main oncogene in t(4;14) MM. Posttranslation modification is one mean of regulating protein-protein interactions, protein stability and activities. A few non-histone proteins have been reported as substrates of histone methyltransferase. [38] [39] [40] NSD1, a member of the NSD (nuclear receptor-binding SET domain protein) family (NSD1, NSD2/MMSET and NSD3), has recently been shown to activate the p65 subunit of NF-κB through methylation of lysine residues K218 and K221. 41 Therefore, it is also possible that MMSET might exert its coactivation activity via methylation of NF-κB.
MM cells are addicted to an abnormal regulatory network controlled by IRF4, making IRF4 an attractive target for the development of antitumor drugs. Lopez-Girona et al. 42 found that baseline IRF4 levels significantly correlate with the sensitivity to lenalidomide in MM cell lines and MM patients. By gene expression microarray analysis, Lopez-Girona et al. 42 established that IRF4 is a key target of lenalidomide and suggested that IRF4 inhibition by lenalidomide may mediate, in part, the antiproliferative and proapoptotic effects of this drug. Recently published data indicated that loss of IRF4 sensitizes MM cells to bortezomibinduced apoptosis. 30 In this study, we found that MMSET knockdown could decrease IRF4 expression and potentiate the effect of bortezomib in vitro and in vivo. We also found that bortezomib could reduce the expression of MMSET and IRF4. These findings might partly explain the additive mechanism of the MMSET knockdown with bortezomib combination. It has been previously reported that bortezomib could downregulate IκBα and activate NF-κB in some MM cell lines. 43 Our data show that in KMS11 cells, bortezomib also enhanced NF-κB activity through the downregulation of IκBα and upregulation of phosphor-p65 but could also reduce the MMSET protein level. The aggregate effect of bortezomib was a decrease in IRF4 expression in KMS11 cells. In two other t(4;14) cell lines (KMS18 and KMS28BM), bortezomib inhibited NF-κB activity through the downregulation of NF-κB p65 and phosphor-p65 levels. These results are consistent with cell proliferation data showing that KMS18 and KMS28BM are more sensitive to bortezomib compared with KMS11 (Figures 4a and c) . Several studies suggest that early, and possibly prolonged, use of bortezomib overcomes the early mortality associated with t(4;14). [44] [45] [46] Our finding that bortezomib reduces MMSET expression may provide a mechanism for its preferential efficacy in t(4;14) MM observed in clinical studies. The precise mechanism by which bortezomib decreases MMSET expression remains elusive and is being actively pursued by our group.
Taken together, our data indicated that MMSET is involved in the regulatory network of transcription factor IRF4, which is critical for MM cell survival, and that MMSET knockdown potentiates the effect of the antimyeloma agent bortezomib in t(4;14) MM cells in vitro and in vivo. Our preclinical studies demonstrate the therapeutic potential of combining MMSET inhibition with bortezomib to improve patient outcome in MM.
